Ekadharma International Tbk (EKAD) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Ekadharma International Tbk IDR 317, price IDR 396, upside -20.0%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ekadharma International Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 153.00 IDR – 450.00 IDR · fair‑value band 251.42 IDR – 391.43 IDR · the 396.00 IDR price screens above the 317.00 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Ekadharma International Tbk in your weekly email
Every Wednesday you see whether Ekadharma International Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Ekadharma International Tbk, together with its subsidiaries, engages in manufacturing and sale of self-adhesive tapes and related supplementary materials in Indonesia and Malaysia. It operates through Sticking Plaster and Others segments.
Show more
PT Ekadharma International Tbk, together with its subsidiaries, engages in manufacturing and sale of self-adhesive tapes and related supplementary materials in Indonesia and Malaysia. It operates through Sticking Plaster and Others segments. The company offers lint roller, accessories, industrial tape, packaging products, and cutters; cloth tape/masking tape products; reflective, PVC electrical, and aluminum foil tape; cling wrap, and aluminum foil; kraft tape; OPP tape, including custom, printed, and OPP color tape; and air column bag products. It also engages in general trading business. The company sells its products under the Daimaru, SUPERFIX, and BESTPACK brands. The company was formerly known as PT Ekadharma Widya Grafika and changed its name to PT Ekadharma International Tbk in 2006. The company was founded in 1981 and is headquartered in Tangerang, Indonesia. PT Ekadharma International Tbk is a subsidiary of PT Ekadharma Inti Perkasa.
Stock analysis
Ekadharma International Tbk (EKAD) currently trades at 396.00 IDR, while our model-based Fair Value estimate is 317.00 IDR, implying the stock looks roughly 24.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 342.19 IDR per share, and 2 of the 23 models we run sit above the 396.00 IDR price.
Bear case: the Earnings-Based group reads lowest at 150.04 IDR, and 21 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: 251.42 IDR (bear) to 391.43 IDR (bull), the price of 396.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Ekadharma International Tbk reported revenue of 530B IDR in FY2025 versus 630B IDR in FY2021, a compound −4.2%/yr. Reported net income was 53.0B IDR in FY2025, compounding −15.6%/yr from FY2021.
Key figures
Market cap 594B IDR (≈ $33.2M) · P/E ratio 1.2 · P/S ratio 0.12 · EPS (TTM) 146.27 IDR · Net margin 10.0% · Return on equity 4.0% · Return on assets (EBIT) 6.7% · Operating margin 9.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 159% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −40% fair-value upside, at −20%, EKAD screens cheaper than that median.
Fair Value models
Bear 251.42 IDRFair Value 317.00 IDRBull 391.43 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (107.40 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Start year 2020 (pandemic). Over 10 years: +0.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−10.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−11% vs 1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 10%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −5.4% a year for the price.
Compare Ekadharma International Tbk with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 712 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside−20% · Above median
Profitability
Return on equity (TTM)4% · Below median
Return on assets2% · Below median
Net margin (TTM)9% · Above median
Operating margin (TTM)9% · Above median
Growth and dividend
Revenue growth11% · Above median
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ekadharma International Tbk Fair Value". https://www.fairvalue-calculator.com/stock/EKAD
Frequently asked questions
Is Ekadharma International Tbk (EKAD) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 317.00 IDR versus a price of 396.00 IDR, about −20% upside (overvalued).
What is the fair value of EKAD?
Our model-based fair value for Ekadharma International Tbk is 317.00 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 396.00 IDR.
What is the quality score of EKAD?
Ekadharma International Tbk has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ekadharma International Tbk (EKAD)?
Our model-based price target is the fair value of 317.00 IDR (as of Sep 24, 2026) from 23 valuation models. Cautious scenario 251.42 IDR, optimistic scenario 391.43 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Ekadharma International Tbk stock forecast for 2026?
Our models put fair value at 317.00 IDR, about −20% upside versus a price of 396.00 IDR (overvalued). Cautious scenario 251.42 IDR, optimistic scenario 391.43 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Ekadharma International Tbk (EKAD)?
Ekadharma International Tbk reported trailing-twelve-month revenue of about 543B IDR (latest available figure, as of Sep 24, 2026).
What growth is priced into Ekadharma International Tbk (EKAD)?
For today's price to be fair in a discounted-cash-flow model, Ekadharma International Tbk would have to grow free cash flow by -2.9 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of EKAD use?
Our models discount Ekadharma International Tbk at 10.5 %: a base by market capitalisation (nano), damped by beta 0.01, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ekadharma International Tbk that is -2.9 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Ekadharma International Tbk (EKAD) delivered so far?
Over the past 5 years revenue at Ekadharma International Tbk grew -4.6 % a year. The price currently implies -2.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ekadharma International Tbk (EKAD) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Ekadharma International Tbk (-2.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ekadharma International Tbk (EKAD)?
The free-cash-flow yield on the price is 6.63 %: that much free cash flow Ekadharma International Tbk produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ekadharma International Tbk (EKAD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ekadharma International Tbk it is 317.00 IDR per share (as of Sep 24, 2026), against a price of 396.00 IDR. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Ekadharma International Tbk stock overvalued or undervalued in 2026?
As of Sep 24, 2026, EKAD trades above its calculated fair value: price 396.00 IDR, fair value 317.00 IDR, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EKAD?
No. The price is what the market pays today (396.00 IDR); the fair value is what the company's own numbers justify (317.00 IDR). For Ekadharma International Tbk the two are 79.00 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Ekadharma International Tbk worth?
The market values Ekadharma International Tbk at about 594B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 396.00 IDR; our models calculate a fair value of 317.00 IDR per share.
What do the bullish and bearish scenarios say about EKAD?
Our models span a range for Ekadharma International Tbk: cautious scenario 251.42 IDR, base 317.00 IDR, optimistic 391.43 IDR per share (as of Sep 24, 2026, price 396.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EKAD?
Ekadharma International Tbk trades at a price-to-earnings ratio of 1.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 317.00 IDR is built from several models across several years.
How solid is the balance sheet of Ekadharma International Tbk (EKAD)?
Balance-sheet figures for Ekadharma International Tbk (as of Sep 24, 2026): return on equity 4.0%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is EKAD from its 52-week high?
Ekadharma International Tbk trades at 396.00 IDR, about 12% below its 52-week high of 450.00 IDR and 159% above the low of 153.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 317.00 IDR is for.
Which stocks are comparable to Ekadharma International Tbk?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ekadharma International Tbk stock attractive at the current price?
The data as of Sep 24, 2026: price 396.00 IDR, calculated fair value 317.00 IDR (−20%), Quality Score 63/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EKAD calculated?
We run Ekadharma International Tbk through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 317.00 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Ekadharma International Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ekadharma International Tbk (EKAD)?
The closing price on Sep 24, 2026 was 396.00 IDR. Our model-based fair value is 317.00 IDR, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ekadharma International Tbk right now?
Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Ekadharma International Tbk (EKAD) come from?
Earnings per share at Ekadharma International Tbk grew +0.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share −0.3 %, EBIT margin −3.0 %, tax rate +1.4 %, residual (interest, one-offs) +2.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ekadharma International Tbk
How large is the market capitalisation of Ekadharma International Tbk (EKAD)?
The market capitalisation of Ekadharma International Tbk is 594B IDR (≈ $33.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ekadharma International Tbk (EKAD)?
The price-to-sales ratio of Ekadharma International Tbk is 0.12 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ekadharma International Tbk (EKAD)?
Earnings per share at Ekadharma International Tbk are 146.27 IDR (price ÷ EPS = P/E 1.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ekadharma International Tbk (EKAD)?
The net margin of Ekadharma International Tbk is 10.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ekadharma International Tbk (EKAD)?
The return on equity (ROE) of Ekadharma International Tbk is 4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ekadharma International Tbk (EKAD)?
On an EBIT basis the return on assets of Ekadharma International Tbk is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ekadharma International Tbk (EKAD)?
The operating margin of Ekadharma International Tbk is 9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ekadharma International Tbk (EKAD)?
Revenue at Ekadharma International Tbk is growing +10.7% versus a year earlier (3y avg −4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ekadharma International Tbk (EKAD)?
Earnings per share at Ekadharma International Tbk are growing −42.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ekadharma International Tbk (EKAD) hold?
Ekadharma International Tbk holds more cash than debt, 57.3B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Ekadharma International Tbk in the live analysis
One click puts Ekadharma International Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
